Labcorp to Offer HPV and STI Self-Collection Options in Labcorp Patient Service Centers and Participating Physician Offices Nationwide
Labcorp (NYSE: LH) announced nationwide rollout of FDA-approved self-collection solutions for HPV and STI testing, available from April 7, 2025. The service will be accessible at over 2,200 Patient Service Centers and participating physician offices across the US.
The initiative addresses critical healthcare gaps, as one in four women are not up-to-date with cervical cancer screenings. With over 13,000 women diagnosed with cervical cancer annually and approximately 4,000 deaths, this preventable disease remains a significant concern. The self-collection option includes testing for HPV and STIs (chlamydia, gonorrhea, trichomonas, and mycoplasma genitalium).
Key features include:
- Physician-ordered testing with private collection options
- Available at 2,200 Labcorp PSC locations
- Electronic results delivery to both physician and patient
- Follow-up with physician required for positive results
Labcorp (NYSE: LH) ha annunciato il lancio a livello nazionale di soluzioni di auto-raccolta approvate dalla FDA per il test HPV e STI, disponibili dal 7 aprile 2025. Il servizio sarà accessibile in oltre 2.200 Centri di Servizio per i Pazienti e negli studi medici partecipanti in tutto il paese.
Questa iniziativa affronta lacune critiche nel settore sanitario, poiché una donna su quattro non è aggiornata con gli screening per il cancro cervicale. Con oltre 13.000 donne diagnosticate con cancro cervicale ogni anno e circa 4.000 decessi, questa malattia prevenibile rimane una preoccupazione significativa. L'opzione di auto-raccolta include test per HPV e STI (clamidia, gonorrea, tricomoniasi e mycoplasma genitalium).
Le caratteristiche principali includono:
- Test ordinati dal medico con opzioni di raccolta private
- Disponibile in 2.200 sedi Labcorp PSC
- Consegna elettronica dei risultati sia al medico che al paziente
- Richiesta di follow-up con il medico per risultati positivi
Labcorp (NYSE: LH) anunció el lanzamiento a nivel nacional de soluciones de auto-recolección aprobadas por la FDA para pruebas de HPV y STI, disponibles a partir del 7 de abril de 2025. El servicio estará accesible en más de 2,200 Centros de Servicio al Paciente y consultorios médicos participantes en todo Estados Unidos.
La iniciativa aborda brechas críticas en la atención médica, ya que una de cada cuatro mujeres no está al día con las pruebas de cáncer cervical. Con más de 13,000 mujeres diagnosticadas con cáncer cervical anualmente y aproximadamente 4,000 muertes, esta enfermedad prevenible sigue siendo una preocupación significativa. La opción de auto-recolección incluye pruebas para HPV y STI (clamidia, gonorrea, tricomoniasis y mycoplasma genitalium).
Las características clave incluyen:
- Pruebas ordenadas por el médico con opciones de recolección privadas
- Disponibles en 2,200 ubicaciones de Labcorp PSC
- Entrega electrónica de resultados tanto al médico como al paciente
- Se requiere seguimiento con el médico para resultados positivos
Labcorp (NYSE: LH)는 2025년 4월 7일부터 사용할 수 있는 HPV 및 STI 검사를 위한 FDA 승인 자가 수집 솔루션의 전국적 출시를 발표했습니다. 이 서비스는 미국 전역의 2,200개 이상의 환자 서비스 센터 및 참여 의사 사무실에서 이용할 수 있습니다.
이 이니셔티브는 4명 중 1명의 여성이 자궁경부암 검진을 최신 상태로 유지하지 않고 있는 등 중요한 의료 격차를 해결합니다. 매년 13,000명 이상의 여성이 자궁경부암 진단을 받고 있으며, 약 4,000명이 사망하는 이 예방 가능한 질병은 여전히 중요한 문제입니다. 자가 수집 옵션에는 HPV 및 STI(클라미디아, 임질, 트리코모나스, 마이코플라스마 제니탈리움) 검사가 포함됩니다.
주요 특징은 다음과 같습니다:
- 의사가 주문한 검사와 개인 수집 옵션
- 2,200개의 Labcorp PSC 위치에서 이용 가능
- 의사와 환자 모두에게 전자 결과 전달
- 양성 결과에 대한 의사와의 후속 조치 필요
Labcorp (NYSE: LH) a annoncé le déploiement national de solutions d'auto-collecte approuvées par la FDA pour les tests HPV et IST, disponibles à partir du 7 avril 2025. Le service sera accessible dans plus de 2 200 Centres de Services aux Patients et cabinets médicaux participants à travers les États-Unis.
Cette initiative répond à des lacunes critiques dans le domaine de la santé, car une femme sur quatre n'est pas à jour avec les dépistages du cancer du col de l'utérus. Avec plus de 13 000 femmes diagnostiquées chaque année avec un cancer du col de l'utérus et environ 4 000 décès, cette maladie évitable reste une préoccupation majeure. L'option d'auto-collecte comprend des tests pour le HPV et les IST (chlamydia, gonorrhée, trichomonase et mycoplasma genitalium).
Les caractéristiques clés incluent:
- Tests ordonnés par le médecin avec des options de collecte privées
- Disponible dans 2 200 sites Labcorp PSC
- Livraison électronique des résultats au médecin et au patient
- Suivi avec le médecin requis pour des résultats positifs
Labcorp (NYSE: LH) hat die landesweite Einführung von FDA-zugelassenen Selbstentnahmelösungen für HPV- und STI-Tests angekündigt, die ab dem 7. April 2025 verfügbar sein werden. Der Service wird an über 2.200 Patientenservicestandorten und teilnehmenden Arztpraxen in den USA zugänglich sein.
Die Initiative schließt kritische Lücken im Gesundheitswesen, da eine von vier Frauen nicht auf dem neuesten Stand der Vorsorgeuntersuchungen für Gebärmutterhalskrebs ist. Jährlich werden über 13.000 Frauen mit Gebärmutterhalskrebs diagnostiziert und etwa 4.000 sterben daran, was diese vermeidbare Krankheit zu einem erheblichen Anliegen macht. Die Selbstentnahmeoption umfasst Tests auf HPV und STIs (Chlamydien, Gonorrhö, Trichomoniasis und Mycoplasma genitalium).
Wichtige Merkmale sind:
- Vom Arzt angeordnete Tests mit privaten Entnahmeoptionen
- Verfügbar an 2.200 Labcorp PSC Standorten
- Elektronische Ergebnisübermittlung an Arzt und Patient
- Nachverfolgung mit dem Arzt erforderlich bei positiven Ergebnissen
- Expansion into new FDA-approved testing services enhances revenue potential
- Leverages existing infrastructure of 2,200 locations for service delivery
- Addresses underserved market with 25% of women behind on cervical cancer screening
- Potential to capture share of 2.4 million annual STI cases market
- Requires physician orders, limiting direct-to-consumer potential
- Success depends on patient adoption and physician referrals
- Faces potential competition from other diagnostic providers
Insights
Labcorp's nationwide deployment of FDA-approved HPV and STI self-collection options represents a strategic market expansion targeting a significant gap in preventive healthcare. The company is addressing a substantial unmet need, with 1 in 4 women not current on cervical cancer screenings and
This initiative leverages Labcorp's extensive infrastructure of 2,200 Patient Service Centers to potentially capture increased testing volume from patients who previously avoided screenings due to discomfort, stigma, or time constraints. By removing these barriers, Labcorp could see meaningful growth in its diagnostic testing business specifically in women's and sexual health segments.
The timing is opportune, following the FDA's 2024 approval of self-collection tests for cervical cancer screening. Labcorp is positioning itself to capitalize on the growing trend toward patient autonomy in healthcare while addressing significant public health concerns - 13,000+ cervical cancer diagnoses and 2.4 million STI cases annually in the US.
This service expansion represents a competitive advancement that could strengthen Labcorp's market position in preventive health diagnostics while potentially improving early detection rates for serious conditions.
New offering expands screening options for cervical cancer and sexually transmitted infections (STIs), including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen)
"Many patients delay or avoid necessary health screenings due to discomfort, stigma or time challenges, which can lead to health complications and further spread infections," said Dr. Brian Caveney, Labcorp's chief medical and scientific officer. "Labcorp is now offering self-collection at our PSCs and healthcare settings such as physician offices to break down these barriers. With convenient access to essential tests and screenings, patients can take control of their health, on their own terms, when it's most convenient for them."
Expanding Access to Cervical Cancer Screening
Each year in the
Traditionally, cervical cancer screening involves a healthcare provider collecting a specimen during a Pap smear and forwarding it to a laboratory for testing. In 2024, the FDA approved self-collection tests for cervical cancer screenings.
"Cervical cancer is preventable, yet screening rates among women in
A Convenient and Private Screening Option for STIs
Labcorp will also offer a vaginal swab self-collect option for STI testing, including chlamydia, gonorrhea, trichomonas or mycoplasma genitalium (Mgen). According to the CDC, 2.4 million cases of STIs were diagnosed and reported in 2023. Early detection can help minimize long-term effects for patients and increase the effectiveness of treatment.
"STI testing can feel intimidating or stigmatizing, which leads to delayed or skipped screenings. Providing a private and discreet self-collection option empowers individuals to take control of their sexual health and can expedite the diagnosis to treatment timeline, ultimately driving better health outcomes," said Dr. Caveney.
Key Features of Labcorp's HPV and STI Self-Collection Offerings:
- Self-collection for both HPV and STI testing can be ordered by a physician and completed in a healthcare setting or one of Labcorp's 2,200 PSC locations nationwide.
- Results are sent electronically to the ordering physician and to the patient via their Labcorp Patient account.
- If positive, patients should follow up with their physician to determine treatment.
Labcorp's new self-collect offerings will be made available beginning April 7. To learn more about self-collect, click here. To find a patient service center near you, visit: https://www.labcorp.com/labs-and-appointments.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than
View original content:https://www.prnewswire.com/news-releases/labcorp-to-offer-hpv-and-sti-self-collection-options-in-labcorp-patient-service-centers-and-participating-physician-offices-nationwide-302416985.html
SOURCE Labcorp
FAQ
When will Labcorp (LH) launch its HPV and STI self-collection testing service?
How many Labcorp locations will offer HPV and STI self-collection testing?
What types of STI tests are included in Labcorp's self-collection offering?
What is the current cervical cancer screening compliance rate according to Labcorp's announcement?
How many cervical cancer cases and deaths occur annually in the US according to Labcorp's release?
